Small molecules to lead Leo Pharma to greatness
In 2030, Leo Pharma wants to be the world’s leading firm within medical dermatology, and the road there is firmly anchored in small molecules, which is what the company’s scientists do best. Big molecules – which will continue to play a role – will be sourced externally.
by ULRICH QUISTGAARD, translated by daniel pedersen
Leo Pharma has no doubts about where the road ahead is leading it. By the end of the decade, the company aims to be one of the absolute biggest international organizations within medical dermatology, and is currently going through sweeping changes to get there.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma to terminate up to 150 R&D jobs
For subscribers
Leo Pharma poaches Novo Nordisk VP to lead US division
For subscribers
